The US Food and Drug Administration came in for criticism from the Government Accountability Office, which last week issued a report saying that the agency is not fulfilling its oversight obligation regarding its Office of Criminal Investigation. The report is the result of a review called for in 2009 by Senator Charles Grassley (Republican, Iowa), Ranking Member of the Senate Committee on Finance.
To improve oversight of its investigations, the GAO recommends that the FDA regularly monitors the OCI, and establishes a process to monitor the Office of Internal Affairs for compliance with its investigative policies. The GAO also recommends that that the FDA should establish performance measures for the OCI to assess whether it is achieving its desired results.
FDA accepts fault and is already taking action, says Commissioner
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze